Rezvoglar Insulin (Insulin Glargine-aglr) KwikPen

Description

Rezvoglar Insulin (Insulin Glargine-aglr) KwikPen – Long-Acting Basal Insulin for Diabetes Management

Rezvoglar™ (insulin glargine-aglr) injection is a high-quality, long-acting insulin glargine biosimilar designed to help adults and pediatric patients with type 1 diabetes and adults with type 2 diabetes achieve better glycemic control. As an FDA-approved interchangeable biosimilar to Lantus, Rezvoglar delivers the same trusted basal insulin action at a more affordable price point, making daily diabetes management more accessible.

Why Choose Rezvoglar Insulin?

• 24-Hour Steady Blood Sugar Control: Rezvoglar provides a smooth, peakless release of insulin that mimics the body’s natural basal insulin, helping maintain stable glucose levels throughout the day and night with just one daily injection.
• Convenient KwikPen Delivery: Available in the easy-to-use Rezvoglar KwikPen (3 mL prefilled pen, 100 units/mL, total 300 units). It allows precise dosing from 1 to 80 units in 1-unit increments—no vial or syringe needed.
• Proven Biosimilar to Lantus: Rezvoglar is highly similar to Lantus (insulin glargine) with no clinically meaningful differences in safety, efficacy, or potency. It is now interchangeable, so pharmacists can substitute it for Lantus prescriptions in many cases without needing prescriber approval.
• Suitable for All Ages: Approved for adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes (when used with diet, exercise, and possibly rapid-acting insulin for type 1).

Key Benefits for Diabetes Patients

• Reduces the risk of high blood sugar (hyperglycemia) while supporting overall metabolic health.
• Flat, consistent action profile with onset around 1 hour, no pronounced peak, and duration of approximately 24 hours or more.
• Helps simplify your insulin regimen compared to shorter-acting insulins.

Important Safety Information: Rezvoglar is for subcutaneous injection only and should be used at the same time each day. Rotate injection sites (abdomen, thigh, or upper arm) to avoid lipodystrophy. It is not for treating diabetic ketoacidosis and should not be used during episodes of low blood sugar (hypoglycemia). Always consult your healthcare provider for proper dosing—typical starting doses are 0.2 units/kg or up to 10 units once daily for insulin-naïve type 2 diabetes patients, or about one-third of total daily insulin needs for type 1.

Common Side Effects may include hypoglycemia, injection site reactions, weight gain, or allergic reactions. Monitor blood glucose regularly and follow your doctor’s instructions closely.

Rezvoglar KwikPen is a prescription-only medication manufactured by Eli Lilly. Pair it with proper diet, exercise, and blood sugar monitoring for optimal results.

Order Rezvoglar Insulin Online Today – Affordable long-acting insulin glargine biosimilar with the convenience of the KwikPen. Improve your diabetes control with a trusted, cost-effective option comparable to Lantus.